Morphine (MOR) Rapid Test

Morphine is a prescription opioid used for severe pain management in selected patients. It may be used after surgery, trauma, cancer pain, or other serious pain conditions where other pain relief options are not suitable. From a drug screening point of view, morphine is important because it may appear due to prescribed medical use, misuse, or exposure to opioid-related substances. The Morphine MOR Rapid Test helps identify possible morphine presence in urine and supports fast decision-making in professional screening programs.

• The MOR rapid test is valuable because opioids require careful monitoring. Morphine may cause serious safety risks when misused, taken with alcohol, combined with sedatives, or used outside medical supervision.
• The Morphine urine rapid test can support drug of abuse screening programs, rehabilitation centers, workplace drug testing panels, clinical toxicology screening, pain-management compliance monitoring, forensic screening, and international diagnostic distribution.
• The MOR rapid test kit does not diagnose addiction, overdose, intoxication, or any medical condition. It only provides a preliminary urine screening result for morphine at the stated 300 ng/mL cut-off.

The Morphine (MOR) Rapid Test by LARKSOIS Pharma may be used in professional diagnostic and institutional screening environments.

Applications

• Drug of abuse screening programs
• Rehabilitation and de-addiction centers
• Workplace drug testing panels
• Clinical toxicology screening
• Pain-management compliance monitoring
• Forensic and legal screening support
• International diagnostic distribution
• Laboratory and institutional drug monitoring workflows

• The Morphine MOR Rapid Test is generally based on a rapid immunoassay principle. In this type of screening, a urine specimen is added to the test device, and the result is visually interpreted according to the product insert.
• The test is designed to detect morphine at or above the defined cut-off level. A proper urine specimen, correct timing, clean handling, and accurate result interpretation are important for dependable screening performance.
• For workplace, clinical, forensic, or legal decisions, a non-negative MOR urine test result should be confirmed by a certified laboratory method. Rapid tests are useful for screening, but confirmation provides greater specificity.

The Morphine (MOR) Rapid Test uses a rapid urine screening method for qualitative detection of morphine. It is designed to provide a preliminary screening result at the stated 300 ng/mL cut-off.

Benefits

• Fast urine-based morphine screening
• 300 ng/mL cut-off for professional testing needs
• Simple rapid test format
• Suitable for laboratories and field screening programs
• Supports drug of abuse testing panels
• Useful for international diagnostic distribution
• Manufactured with LARKSOIS Pharma quality focus

The Morphine (MOR) Rapid Test is designed for urine specimens. Urine is widely used in drug screening because it is practical, non-invasive, and suitable for professional toxicology screening workflows.

Guidance

• Use urine specimens only
• Use a clean urine specimen container
• Follow the package insert carefully
• Read results only within the stated time
• Do not reuse the test device
• Treat all urine samples as potentially biohazardous
• Confirm important results through laboratory testing

Note

A rapid screening result should be considered preliminary unless confirmed by a validated laboratory method where required.

The Morphine (MOR) Rapid Test by LARKSOIS Pharma has a stated cut-off of 300 ng/mL. This means the test is designed to screen urine specimens for morphine at or above the validated threshold. LARKSOIS Pharma should mention the exact performance details according to the final product insert, technical file, and regulatory documentation.

Instructions

• Fast urine-based morphine screening
• 300 ng/mL cut-off for professional testing needs
• Simple and easy-to-read rapid test format
• Suitable for laboratories and field screening programs
• Supports drug of abuse testing panels
• Useful for workplace, clinical, forensic, and rehabilitation settings
• Designed for international diagnostic distribution
• Manufactured with LARKSOIS Pharma quality focus

Note

The Morphine MOR Rapid Test by LARKSOIS Pharma is created for professional users who need a practical, efficient, and reliable preliminary screening solution.

Steps

• Bring the test device and urine specimen to the recommended testing condition
• Open the sealed pouch only when ready to test
• Collect urine using a clean sample collection procedure
• Apply the urine specimen according to the product insert
• Wait for the test reaction to complete within the instructed time
• Read the result within the approved interpretation window
• Dispose of used materials according to laboratory safety rules

Note

The exact procedure must follow the official LARKSOIS Pharma product insert supplied with the Morphine (MOR) Rapid Test.

Positive

A positive or non-negative result suggests that morphine may be present in the urine specimen at or above the stated cut-off. Positive results are preliminary and should be confirmed using a recognized laboratory method where required.

Negative

A negative result suggests that morphine was not detected or was below the cut-off at the time of testing. A negative result does not always rule out exposure if sample quality, collection timing, or the detection window affects the result.

Invalid

If the valid control indicator does not appear, the test is invalid. The test should be repeated with a new device and fresh urine specimen according to the product insert.

Instructions

• Store according to the product label and package insert
• Keep the test sealed until use
• Protect it from direct sunlight, moisture, and extreme temperatures
• Do not use expired or damaged test devices
• Use a clean urine specimen container
• Read results only within the stated time
• Do not reuse the test device

Instructions

• For professional screening use only
• Use urine specimen only as directed
• Do not reuse the test device
• Follow the product insert carefully
• Handle all urine specimens as potentially infectious material
• Do not interpret results after the recommended reading time
• Confirm presumptive positive results with laboratory testing
• Follow applicable drug testing laws and reporting requirements

LARKSOIS Pharma provides internationally focused pharmaceutical and diagnostic products for professional healthcare and screening markets. The Morphine MOR Rapid Test is developed for distributors, laboratories, hospitals, rehabilitation centers, workplace testing providers, and global diagnostic buyers.

Advantages

• International diagnostic product focus
• Reliable rapid testing solutions
• Suitable for laboratories and healthcare suppliers
• Distributor-friendly product format
• Supports drug of abuse screening programs
• Designed for practical urine screening workflows
• Quality-focused standards under LARKSOIS Pharma